Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – What’s Next?

Posted by Brian Himes on Nov 5th, 2026

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday. The company traded as low as $20.40 and last traded at $20.3950, with a volume of 358,869 shares changing hands. The stock had previously closed at $20.47.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on GPCR shares. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Weiss Ratings downgraded Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $110.91.

Check Out Our Latest Stock Analysis on GPCR

Structure Therapeutics Trading Down 6.5%

The stock’s 50-day moving average is $31.09 and its two-hundred day moving average is $48.17.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Principal Financial Group Inc. grew its stake in Structure Therapeutics by 36.6% during the 1st quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock worth $84,531,000 after purchasing an additional 469,554 shares in the last quarter. Orbimed Advisors LLC raised its stake in Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after buying an additional 313,600 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after acquiring an additional 264,833 shares in the last quarter. Siren L.L.C. increased its holdings in shares of Structure Therapeutics by 23.2% in the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock valued at $64,043,000 after acquiring an additional 250,000 shares during the last quarter. Finally, SEB Asset Management AB acquired a new stake in shares of Structure Therapeutics during the 1st quarter worth about $11,811,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.